Please login to the form below
asthma drug
This page shows the latest asthma drug news and features for those working in and with pharma, biotech and healthcare.
AZ, Amgen file first-in-class asthma drug with the FDA
AstraZeneca (AZ) and Amgen have submitted a biologic license application (BLA) for their first-in-class asthma drug tezepelumab to the US Food and Drug Administration (FDA). ... In September 2018, tezepelumab scored a breakthrough therapy designation (BTD
Latest news
-
FDA approves new self-injection administration for Xolair
Drug is approved for asthma and other allergic and inflammatory conditions. ... This includes a number of allergic and inflammatory conditions, including moderate-to-severe persistent allergic asthma, chronic idiopathic urticaria (CIU) and nasal polyps.
-
Oxford study finds standard asthma medication improves recovery time in COVID-19 patients
Inhaled budesonide – a type of corticosteroid medication – is commonly used to treat asthma and chronic obstructive pulmonary disease. ... The inhaled asthma drug was given to 751 people within the first two weeks of symptom onset, while 1, 028 were
-
AZ, Amgen’s tezepelumab reduces asthma exacerbations in broad patient population
an asthma drug. ... In September 2018, tezepelumab scored a breakthrough therapy designation (BTD) from the US Food and Drug Administration (FDA) in patients with severe asthma without an eosinophilic phenotype.
-
Pfizer, Sanofi and others set to increase US drug prices in 2021
Generic drugmaker Teva Pharmaceuticals has also raised the prices on 15 drugs, including rare neurological disorders drug Austedo (deutetrabenazine), asthma steroid Qvar (beclometasone) and more. ... One key tenet of Biden’s drug pricing pledge is to
-
Synairgen’s SNG001 advances into phase 3 COVID-19 trial
UK biotech had initially been testing drug for COPD and asthma. ... response. Initially, Synairgen had been evaluating the drug as a treatment for COPD and asthma, although its focus has now shifted to investigating SNG001’s potential in COVID-19
FDA approves new self-injection administration for Xolair
Oxford study finds standard asthma medication improves recovery time in COVID-19 patients
AZ, Amgen’s tezepelumab reduces asthma exacerbations in broad patient population
Pfizer, Sanofi and others set to increase US drug prices in 2021
More from news
Approximately 2 fully matching, plus 125 partially matching documents found.
Latest Intelligence
-
GSK forges ahead with its dynamic COPD and asthma portfolio
You would imagine coronavirus would be one of those threats.”. GSK is trialling its biologic anti IL-5 drug mepolizumab, licensed for severe asthma, in eosinophilic COPD with a new phase ... The company is also forging ahead with biologics research in
-
The long and winding road to asthma breakthroughs
This was the turning point for the development programme.”. The late nights interrogating the science and unpicking data sets prompted the switch from a drug for the broad asthma community to ... a therapy targeted at a subtype representing around 10%
-
Cancer immunotherapy: What's on the horizon?
Researchers are now trying to identify biomarker-based subgroups and drug combinations to try to improve therapeutic outcomes for patients. ... up innate immune responses, and Cancer Research UK is repurposing an AZ chemokine CCR4 receptor drug (AZD2098)
-
US health reforms
In fact, it’s safe to say most C-suite drug executives would hardly shed a tear upon news of Obamacare’s swift demise. ... To cite just one example, patients with financial need get an 85% discount on the popular asthma drug Advair, and that’s by
-
Building BRICs: pharma's key emerging markets are becoming giants
In April 2013, Novartis was denied patent protection for its cancer drug, Glivec, by the Indian Supreme Court. ... This follows similar patent defeats in India for Pegasys, Roche's hepatitis drug, Merck's asthma treatment, Singulair, Gilead's Viread (HIV)
GSK forges ahead with its dynamic COPD and asthma portfolio
The long and winding road to asthma breakthroughs
Cancer immunotherapy: What's on the horizon?
US health reforms
Building BRICs: pharma's key emerging markets are becoming giants
More from intelligence
Approximately 0 fully matching, plus 5 partially matching documents found.
Latest appointments
-
Enterprise Therapeutics appoints CEO
He joins the drug discovery firm from Xention Discovery, where he had served as chief scientific officer since co-founding the company in 2002. ... Discovery. Dr Peter Finan, chairman of Enterprise Therapeutics, said: “John's experience in ion channels,
-
Former RBS head takes the reins as GSK chair
the past year, and to develop new products in order to offset the decline of its best-selling asthma drug, Advair, as part of his new remit.
Enterprise Therapeutics appoints CEO
Former RBS head takes the reins as GSK chair
More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Account Manager - Creative Healthcare Communications - South Wes...
-
Excellent Remuneration
- Senior Account Manager/ Account Director
-
Competitive Salary Offered
- Head of Strategic Planning, Healthcare Advertising/ Brand comms,...
-
Six figure salary
- Group Account Director, Healthcare Advertising/ Brand comms, Lon...
-
8 month contract up to £90K
-
Account Manager
-
Competitive Salary
- Senior & Principal Medical Writer
-
Competitive Salary Offered
- Account Manager / Senior Account Manager - Creative MedComms - C...
-
Excellent Remuneration
-
Medical Editor
-
Competitive Salary
- Senior Medical Writer– Medical Education – Oxford - London
-
Excellent Remuneration Package
-
Account Management
-
Competitive Salary Offered
-
Senior Account Executive
-
Competitive Salary
- Senior Account / Programme Manager - MedComms - Buckinghamshire
-
Highly Competitive Remuneration packages
-
Associate Account Director
-
Competitive Salary
- Medical Writers (All levels) Editorial / Scientific Leads & ...
-
Highly Competitive Remuneration packages
-
Senior Medical Writer
-
Competitive Salary
-
Publications Director
-
Competitive Salary
- Novavax announces further delays for regulatory filings of COVID-19 vaccine
- Merck & Co reveals plans for women’s health spinoff Organon
- Positive results for GSK/CureVac’s COVID-19 vaccine
- EMA launches rolling review of GSK/Vir Biotech’s mAb for early COVID-19
- Biogen and Capsigen to collaborate on gene therapies
- CanSinoBIO considers booster jab for COVID-19 vaccine
- Research Partnership’s MedTech Division appoints two Directors
- VMLY&Rx launches new payer agency in the US
- Biogen and Envisagenics to advance RNA splicing research for CNS diseases
- Positive results for GSK/CureVac’s COVID-19 vaccine
- New trial data for Keytruda in triple-negative breast cancer
- NICE recommends Keytruda for colorectal cancer patients with rare mutations
- Merck & Co reveals plans for women’s health spinoff Organon
- UK launches subscription-style payment pilot to incentivise pharma antibiotics R&D
- Why female mentorship is so powerful in pharma
- Positive results for GSK/CureVac’s COVID-19 vaccine
- Avoiding A Series of Unfortunate Events: launch lessons from lockdown
- Can protein degraders unlock ‘undruggable’ drug targets?
PMHub
IGNIFI
We’re IGNIFI. An independent creative agency, we help spark and sustain successful brands for some of the biggest names in...
Latest intelligence
- How innovating study sites can improve patient recruitment efficiency
- There are so many ways that clinical trials have innovated over the last few years. There is now a larger focus on making trials more patient-centric, more virtualised, and more...
- Avoiding A Series of Unfortunate Events: launch lessons from lockdown
- Chris Ross takes a novel look at launch excellence through the lens of COVID-19 and explores how pharma’s launch leaders are rewriting the story...
- 6 reasons patients drop out of clinical trials and 6 ways to fix it
- If you’ve successfully recruited patients for your clinical trial, but one by one, they begin to drop out, then this information could be for you....
